In contrast to CCDC71 and KLRC3, MARK2 and GATA2 had a relative abundance of targeted drugs and were associated with a variety of immune cells, which were important potential therapeutic targets for APS and RIF. This evidence concerns the gene MARK2 and autoimmune polyendocrinopathy.